Maxygen - kaufenswert?? - 500 Beiträge pro Seite

[Alemanne]

Hab ich gerade eben gefunden. Kann einer was damit anfangen? Für Tips wäre ich dankbar Maxygen erhält Patent


Maxygen (Nasdaq: MAXY, WKN: 931314) gaben heute bekannt, dass sie ein Patent unter der Nr. 6.096.548 erhalten haben.

Mit diesem Patent wird die MolecularBreeding™-Technologie geschützet, die zur Entwicklung viraler Vektoren, mit verbesserten Fähigkeiten für das Uafspüren der target-Zellen.
Die patentierten Methoden könnten sich nach Unternehmensangaben nützlich für die Entwicklung verbesserter Impfstoffe und Gentherapie-Vektoren erweisen.

[Strong Gainer]

Heute ja!

[Clark-W.Griswaldt]

warum heute denn?

[Strong Gainer]

Warum explodiert Maxygen außerbörslich?

[Braini]

Da gabs ne meldung über ein patent. moment ich versuchs mal reinzukopieren...
auch zu lesen unter
http://www.daytrader.via.t-online.de/


Wednesday September 13, 5:07 pm Eastern Time
Press Release
SOURCE: Maxygen Inc.
Maxygen Awarded Broad Patent Expanding Its Leadership Position in Directed Molecular Evolution
REDWOOD CITY, Calif., Sept. 13 /PRNewswire/ -- Maxygen (Nasdaq: MAXY - news) today announced the issuance of U.S. Patent No. 6,117,679 expanding its patent position with respect to its proprietary MolecularBreeding(TM) directed molecular evolution technologies. The new patent has claims covering a variety of in vivo DNAShuffling(TM) recombination methods and formats, claims which expand its rights relating to the use of DNAShuffling(TM) processes in vitro, and claims covering methods for enhancing such processes.

``We are very pleased to have Maxygen`s pioneering work in the field of directed molecular evolution further recognized with the issuance of this patent,`` said Russell Howard, CEO of Maxygen. ``The U.S. Patent Office awarded Maxygen this patent after extensive consideration of a wide range of prior art references. The issuance of this patent strengthens our already broad patent portfolio, and further validates our position as the industry leader in the development and application of our proprietary directed evolution technologies for the creation of products in diverse industries.``

With the issuance of this patent, Maxygen`s intellectual property estate consists of 33 issued U.S. and international patents, including both patents owned by and licensed to Maxygen. Maxygen also has over 400 pending U.S. and international counterpart applications that it has filed on its own behalf or licensed from others.

Maxygen, Inc. headquartered in Redwood City, California, is focused on creating novel products using its proprietary directed evolution technologies for a broad range of industries. Maxygen`s revolutionary technologies bring together the advances in molecular biology and classical breeding while capitalizing on the large amount of genetic information generated by genomics. These proprietary technologies have been published extensively in prestigious publications including Nature, Nature Biotechnology, Nature Medicine, and Science. Maxygen currently has a pipeline of over 40 potential products in its four major target markets of protein pharmaceuticals, preventative and therapeutic vaccines, chemicals and agriculture. Maxygen has strategic collaborations with several leading companies including Novo Nordisk, DuPont, Pfizer, DSM, AstraZeneca, and Rio Tinto as well as government funding from DARPA and NIST-ATP.

Except for the historical information contained herein, this news release contains forward-looking statements including those relating to the ability to obtain competitive commercial benefits from patents, the future research direction of Maxygen and the success of that research. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Among other things these risks and uncertainties include, but are not limited to the inability to produce viable product candidates or products with desired attributes, changing corporate research goals and the future ability of Maxygen to enter into and/or maintain research and commercialization collaborations. These and other risk factors are more fully discussed in Maxygen`s Annual Report on Form 10-K for the year ended December 31, 1999, including under the caption ``Risk Factors``, and in Maxygen`s other periodic reports filed with the SEC, all of which are available from Maxygen or from the SEC`s website (www.sec.gov). Maxygen disclaims any obligation to update or revise any forward-looking statement contained herein to reflect any change in Maxygen`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based. MolecularBreeding(TM), DNAShuffling(TM) and Maxygen are U.S trademarks used by Maxygen.

SOURCE: Maxygen Inc.

[Strong Gainer]

Wenn wir Dich nicht hätten Braini!

[Mongoman]

Interessiert sich denn keiner für MAxygen.

Ich habe zwar auch noch keine MArk damit verdient aber das kommt noch.
Ist ne Super Firma und in vielen Bereichen tätig und hat viele Verträge mit großen Pharmafirmen.

[Mongoman]

Interessiert sich denn keiner für MAxygen.

Ich habe zwar auch noch keine MArk damit verdient aber das kommt noch.
Ist ne Super Firma und in vielen Bereichen tätig und hat viele Verträge mit großen Pharmafirmen.